BioXcel director granted 17,000 stock options

BioXcel Therapeutics director Rajiv Patni received a grant of 17,000 stock options on January 9, 2026.

Rhea-AI Filing Summary

BioXcel Therapeutics director Rajiv Patni received a grant of 17,000 stock options on January 9, 2026. The options have an exercise price of $2.01 per share and give the right to purchase 17,000 shares of BioXcel Therapeutics common stock.

These options were reported as acquired at a price of $0 for the derivative itself, with 17,000 derivative securities beneficially owned after the transaction, all held directly. The options expire on January 9, 2036 and will vest on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders, subject to Patni continuing to serve as a non-employee director through that vesting date.

Insider Trade Summary

Grant/Award: 17,000 shares

Grant/Award 1 txn

Insider Patni Rajiv

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 17,000 contracts (Direct)

Footnotes (1)

1. F1. The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BTAI director Rajiv Patni report?

Director Rajiv Patni reported receiving a grant of 17,000 stock options on January 9, 2026, giving him the right to buy 17,000 shares of BioXcel Therapeutics common stock.

What are the key terms of Rajiv Patni’s BioXcel stock options?

The options are a Stock Option (Right to Buy) with an exercise price of $2.01 per share, covering 17,000 shares, and expiring on January 9, 2036.

How and when do Rajiv Patni’s BTAI options vest?

The options vest on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders, provided he continues serving as a non-employee director through that date.

How many BioXcel options does Rajiv Patni own after this transaction?

Following the reported grant, 17,000 derivative securities (stock options) are shown as beneficially owned by Rajiv Patni, held in direct ownership.

What transaction code is used for this BTAI Form 4 filing?

The transaction is coded “A”, indicating an acquisition of derivative securities, specifically a stock option grant.

Is Rajiv Patni an officer or large shareholder of BioXcel Therapeutics (BTAI)?

In this report, Rajiv Patni is identified as a director of BioXcel Therapeutics and is not listed as an officer or a 10% owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 07:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patni Rajiv

(Last) (First) (Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN CT 06511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.01	01/09/2026		A		17,000		(1)	01/09/2036	Common Stock	17,000	$0	17,000	D

Explanation of Responses:

1. The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.

	/s/ Richard Steinhart, Attorney-in-Fact for Rajiv Patni	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.